🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,80 EUR

Máx. histórico

912,40

64 días

Caída desde máximo

-10,59%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,03%

Cierre anterior

815,60

Rango de hoy

788,80 – 815,80

Volumen hoy

102.849

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,83 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
1.005,32 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 1 día
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
25/08/2020 200,00 203,40 197,10 200,00 +0,76% 3,15% 139.465
24/08/2020 200,80 204,00 197,90 198,50 -0,45% 3,04% 100.655
21/08/2020 201,00 203,80 197,40 199,40 -0,15% 3,18% 105.521
20/08/2020 202,00 205,60 198,40 199,70 -0,94% 3,56% 89.751
19/08/2020 202,40 211,40 199,00 201,60 +0,00% 6,13% 217.197
18/08/2020 202,80 207,60 201,00 201,60 -1,08% 3,25% 143.041
17/08/2020 199,00 204,80 198,70 203,80 +3,24% 3,07% 138.549
14/08/2020 201,60 203,00 196,70 197,40 -1,69% 3,13% 68.564
13/08/2020 199,00 204,40 198,50 200,80 +0,96% 2,96% 137.699
12/08/2020 197,00 199,00 194,00 198,90 +0,96% 2,54% 77.798
11/08/2020 194,00 197,90 193,00 197,00 +1,91% 2,53% 73.772
10/08/2020 198,20 198,20 192,10 193,30 -2,96% 3,08% 66.494
07/08/2020 194,70 199,20 192,80 199,20 +1,79% 3,29% 89.878
06/08/2020 196,80 200,00 194,40 195,70 -0,91% 2,85% 73.254
05/08/2020 196,00 199,10 195,10 197,50 +1,02% 2,04% 97.294
04/08/2020 204,00 206,00 195,00 195,50 -4,17% 5,39% 98.177
03/08/2020 195,00 204,00 192,90 204,00 +4,40% 5,69% 117.538
31/07/2020 198,40 201,40 195,00 195,40 -3,46% 3,23% 142.611
30/07/2020 215,00 217,20 194,60 202,40 -6,30% 10,51% 282.144
29/07/2020 218,20 221,80 214,40 216,00 -1,91% 3,39% 106.284
28/07/2020 220,20 222,80 218,20 220,20 +0,55% 2,09% 69.879
27/07/2020 216,80 221,00 216,40 219,00 -0,18% 2,12% 82.871
24/07/2020 222,80 225,00 215,60 219,40 -4,28% 4,22% 115.683
23/07/2020 224,40 231,00 223,40 229,20 +1,96% 3,39% 70.755
22/07/2020 230,00 231,00 223,20 224,80 -3,52% 3,39% 85.517
21/07/2020 238,60 239,60 232,00 233,00 -1,52% 3,19% 63.578
20/07/2020 232,00 238,40 230,80 236,60 +1,98% 3,28% 90.195
17/07/2020 227,00 232,60 227,00 232,00 +2,47% 2,47% 119.465
16/07/2020 224,40 227,40 222,80 226,40 +0,09% 2,05% 50.243
15/07/2020 222,80 227,00 221,20 226,20 +2,91% 2,60% 56.981